

4th quarter report and preliminary financials for 2020

- Sales for the quarter ended at MNOK 94.2 (MNOK 95.7), a decrease of 1.6%. Sales for 2020 ended at MNOK 363.1 (MNOK 363.7).
- Operating result (EBIT) for the quarter ended at MNOK 22.1 (MNOK 19.7) a 12.1% increase. Operating result the year 2020 ended at MNOK 95.5 (MNOK 89.8), a 6.4% increase. This is the best operating result for a year ever.
- Cashflow from operations was a solid MNOK 74.3. Cash by the end of the year was MNOK 71.9 after a dividend of MNOK 50.1 in November.
- Medistim has entered a Distribution agreement with LivaNova for India.
- The Board will suggest to the General Meeting a dividend of NOK 3.00 per share.

Letter from the CEO

2020 started off on a high note, with record sales in the first quarter, indicating that Medistim was on track to deliver its 10th consecutive year of profitable growth. But, due to the severe implications from the COVID-19 pandemic we ended the year with sales on par with 2019.

However, quickly adapting to the situation, Medistim found ways to manage the new challenges and ended the year with all-time-high operating profit and a strengthened cash position, confirming our market position and robust business model.

During this **unprecedented year** we experienced that hospitals all over the world, understandably, prioritized COVID-19 patients over elective surgeries.

Widespread travel- and hospital access restrictions limited marketing activities and delayed sales projects. This impacted demand for Medistim products in 2020. On-site presence for demonstrations and facilitation of clinical evaluations are critically important steps in our sales and purchasing process. We also normally rely on conferences and in-person meetings to promote our products and influence clinical practice.

On the other hand, through our efforts to adapt to this new situation we found **new ways of cooperating and performing our business**, ways that may provide great opportunities for us in the future.

Digital opportunities

To address the challenges, we did as many others in 2020; "we went digital". We quickly adapted to using digital platforms for conferences and meetings with our customers as well as suppliers, distributors, investors, and other stakeholders. Our experience is that it is possible to maintain close contact, exchange information, influence, and make business progress – all while saving cost and time by just becoming more efficient.

By applying digital communication platforms and remotely controlling our ultrasound systems, we were even able to give product demonstrations and end user training. **This has opened new ways for developing future customer relations and support**. And while we look forward to meeting people in person in 2021, we will continue to take advantage of these technology-enabled opportunities in the future.

Medistim's vision is to become standard-of-care in the operating room, all around the globe. In 2020, sales in all regions were impacted as the pandemic reduced surgical activity. This was offset by higher sales in Japan early in year following the MiraQ regulatory approval in late 2019 and favorable currency effects in Asia and Europe.

The U.S market continues to be **the most important near-term growth driver for the company**. This was reflected in our team signing 25 new accounts in a challenging year and

underpins our expectation of renewed growth into 2021. Longer term, we expect **emerging economies to increasingly contribute to Medistim's growth**. The distributor agreement signed with LivaNova in 2020 for India is an important milestone in that respect.

The pandemic is not yet behind us. Still, **we saw a decreasing impact on our business from the pandemic's initial onset** in the second quarter as the year progressed. We expect to gradually move towards a more normal situation over the course of 2021 and resume more traditional customer interaction by balancing in-person and digital communication. The roll-out of mass vaccination will hopefully create herd immunity and enable societies to re-open and hospitals to attend to all patient groups. While there may be a backlog of postponed surgeries which provides an upside potential, the most important factor for us is that **the need for Medistim's products has not diminished**.

Innovation and people - the secret of our success

Our customers, cardiac and vascular surgeons, are experts in their fields. They are progressive, innovative and technology savvy in their desire to improve outcomes of surgery for their patients. The expectations they set for industry partners and medical equipment are growing and becoming increasingly sophisticated. For Medistim it means that **we need to continue product and solution innovation**.

We have therefore created a dedicated innovation team to maximize efficiency of prototyping and testing of new solutions and devices. Some of the team members have background from artificial intelligence and virtual reality and will challenge established thinking on how our devices should operate. We are excited to continue these efforts in 2021 and to bring innovation to our customers over the years to come.

Our employees are our most critical asset and the protection of their health is our number one priority. We are relieved that the pandemic to date has not brought any serious health issues upon us.

With our 120 employees in Norway and international subsidiaries, supported by a distributor network in more than 60 countries, trusted business partners, long-term owners, and our board of directors; the Medistim team is well equipped to continue our journey of profitable growth.



February 2021
Kari E. Krogstad
President and CEO

4th quarter report and preliminary financials for 2020

The financial report as per December 2020 has been prepared according to the IFRS (International Financial Reporting Standard) and follows IAS 34 for interim financial reporting, as do the comparable numbers for 2019.

FINANCIAL DEVELOPMENT

(Comparative numbers for 2019 in parenthesis.)

Sales and geographic split

Sales in the 4th quarter ended at MNOK 94.2 (MNOK 95.7). In NOK, there was growth in Europe while in the other geographical regions there was a decline in sale for the quarter. Sales in Europe grew by 19.3%, while sales in USA, Asia and "Rest of the world" were down 23.2%, 17.7% and 15.9%, respectively. Sales of own products in Europe was up by 12.1% and third party grew by 33.4%.


Sales for the full year ended at MNOK 363.1 (MNOK 363.7). There was growth in NOK of 12.0% in Asia, while the USA and "Rest of the world" were down by 7.1% and 24.2%, respectively. Europe was up in sales with 5.7% as a region, with sales of own products growing by 10.3% while third party products were at the same level as last year.

The reason for the overall lack of growth in sales seen in the 4th quarter and in 2020, was related to the COVID-19 pandemic and the hospitals' lowered capacity for elective surgical procedures. Both favorable currency and high sales of the recently approved MiraQ™ platform in Japan have helped to offset the decline in NOK.

To get a better understanding of the underlying decrease in surgical procedure level in 2020, good measures are the reduction in number of procedures of about 10% in the USA and 13% outside of the USA. This corresponds reasonably well with the currency neutral revenue decline in own products of 7.3% for the year.

This decrease is not dramatic, and we see tendency of recovery, as the currency neutral decline in Q4 of 7.2% continues to drop from the 9.7% decline seen in Q3 and the 19.3% decline in Q2. With increasing effect of the global vaccination efforts, we expect to see further recovery going forward into 2021.

Split between recurring sales and capital sales in TNOK



Sales of Medistim's own products can be split into capital sales of systems and repeating sales of probes, smartcards, and lease revenue, which are all defined as recurring revenue. In recent years, recurring sales were around 70% of total sales of own products. For 2020, the recurring sales represented 69%.

Split of sales between own products and third party products

Sales of own products for the quarter amounted to MNOK 72.9 (MNOK 79.7). Sales of third party products ended at MNOK 21.2 (MNOK 15.9).

Sales of own products in 2020 amounted to MNOK 295.6 (MNOK 295.7). Sales of third party products ended at MNOK 67.5 (MNOK 68.1).

Split of sales between Cardiac and Vascular segment

For sales of own products, MNOK 61.7 (MNOK 64.6) was within the cardiac segment and MNOK 11.2 (MNOK 15.1) was within the vascular segment for the quarter.

For 2020, sales of own products within the cardiac segment was MNOK 250.5 (MNOK 252.4) and MNOK 45.1 (MNOK 43.3) was within the vascular segment. Hence, the vascular segment represents 15.2% (14.6%) of sales of own products in 2020.

Currency effect

With the same rates as in 2019 sales would have amounted to MNOK 88.8 for the quarter, which represents a currency-neutral decline of 7.2%. Currency-neutral decline of own products was 15.3%, while third party products increased by 33.4% compared to last year.

For 2020 there was a currency-neutral decline of 6.1%. Currency-neutral decline of own products was 7.3%, while third party products was at the same level as last year.

Cost of goods sold

Cost of goods sold (COGS) ended at MNOK 22.2 for the quarter (MNOK 19.8) and represents 23.6% of total sales (20.7%).

Cost of goods sold (COGS) ended at MNOK 76.6 for 2020 (MNOK 80.1) and represents 21.1% of total sales (22.0%).

Positive currency effects explain the decrease in COGS in percent of sales for both the quarter and for the year 2020.

Salary, social and other operating expenses

Salaries and social expenses ended at MNOK 32.2 (MNOK 35.2) for the quarter. Other operating expenses amounted to MNOK 11.3 (MNOK 16.1) for the quarter.

Salaries and social expenses for the full year ended at MNOK 119.1 (MNOK 122.0). Other operating expenses amounted to MNOK 48.9 (MNOK 53.8) for 2020.

R&D expenses

For the quarter, MNOK 4.7 (MNOK 3.3) was spent on research and development (R&D). During the quarter, MNOK 1.2 (MNOK 0.9) of the R&D expense was activated in the balance sheet.

The result before R&D, depreciation and write-offs was MNOK 31.9 (MNOK 26.9). This equals a margin of 33.9% (28.2%).

For 2020, MNOK 16.5 (MNOK 12.4) was spent on research and development (R&D). In 2020, MNOK 1.9 (MNOK 4.6) of the R&D expense was activated in the balance sheet.

The result before R&D, depreciation and write-offs was MNOK 133.1 (MNOK 115.6). This equals a margin of 36.6% (28.5%).

Earnings

Operating profit before depreciation and write-offs (EBITDA) for the quarter ended at MNOK 28.4 (MNOK 24.5). The result before tax and finance (EBIT) ended at MNOK 22.1 (MNOK 19.7).

For 2020, operating profit before depreciation and write-offs (EBITDA) ended at MNOK 118.6 (MNOK 107.8). The result before tax and finance (EBIT) ended at MNOK 95.5 (MNOK 89.8), which is the best EBIT result ever.

Net finance ended negative with MNOK 2.2 for the quarter (positive MNOK 0.4). For 2020 net finance ended negative with MNOK 3.9 (Positive MNOK 1.3). Net finance was related to realized and unrealized gains or losses related to currency, hedging contracts, cash in USD and EUR and customer receivables.

The result before tax was MNOK 19.9 (MNOK 20.2) for the quarter. The result after tax for the quarter was MNOK 13.9 (MNOK 15.5). For 2020, result before tax ended at MNOK 91.6 (MNOK 91.0). Result after tax ended at MNOK 69.4 (MNOK 70.3).

The result per share for the quarter was NOK 0.75 (NOK 0.85). The result per share year for 2020 was NOK 3.81 (NOK 3.87). Average number of shares outstanding was 18,200,391 (18,188,836) at the end of December 2020.

Balance sheet

Equity by the end of 2020 was MNOK 256.8 (MNOK 236.9). This equals an equity ratio of 74.% (70.5%).

The balance sheet ended at MNOK 345.8 from MNOK 336.1 at the beginning of the year.

Cash from operations at year end, ended at MNOK 74.3 despite the increase in inventory. The cash position at the end of December ended at MNOK 71.9. The company had MNOK 10.6 in interest-bearing debt and MNOK 30.1 in obligations related to lease contracts that are recognized in the balance sheet according to IFRS 16.

OPERATIONAL STATUS

Europe

The growth in sales of own products in Europe was driven by strong system sales in Nordic with 46% growth from replacing old installations. There was also a solid growth in UK with 30% growth in sales. Medistim had modest sale in UK in 2019 and despite COVID 19. 3 ultrasound imaging systems were sold. 2020 was a good year for Medistim in Russia. Installed base continued to increase and solid probe sales resulted in a 75% growth in sales compared to 2019.

USA


Medistim offers several business models in the USA, including sales of procedures, leasing, and capital sales.

For the quarter, sales ended at MNOK 26,9, a decrease by 23.2% in NOK. Currency neutral sales decreased with 27.8%. Similar for 2020, sales ended at MNOK 126,4, a decline of 7.1% in NOK. Currency neutral decline was 12.6%. The decline for the quarter and the year is due to the COVID 19 situation. However, even with limited access to hospitals the number of new customers in 2020 was 25.

For the quarter, a total of 13,899 procedures were sold, compared to last year's 15,625. 1,935 (2,818) were imaging procedures and 11,964 (12,834) flow procedures. Capital sales were 3 (8) units.

For 2020, a total of 56,059 procedures were sold, compared to last year's 62,439. 8,803 (10,233) were imaging procedures and 47,256 (52,206) flow procedures. Capital sales were 26 (33) units.

Number of procedural sales per quarter in the USA



In the USA, about 70% of bypass surgeries are performed with no quality assurance of blood flow other than surgeons using their fingertips to check for a pulse. It is clinically proven that this method is not reliable. There is therefore a large potential and need for Medistim's products, and the company has high ambitions in the U.S. market. So far, Medistim has achieved a market penetration of about 23% of the total market of approximately 200,000 bypass surgery procedures performed annually. Medistim has a market penetration of > 80% in Germany, Scandinavia and Japan. Medistim expects that the market penetration in the USA will develop in the same manner over time.

Asia

Asia saw a 17.7% decline in sales for the quarter. However, for 2020 sales increased with 12.0% compared to last year. The sales increase was mainly driven by Japan, where system sales showed strong growth in the first half, after the introduction of MiraQ in late 2019.

Medistim signed a Distributor Agreement with LivaNova for distribution of Medistim products in India by end of the quarter. With its population size of about 1,4 billion, India is a large and emerging market for Medistim's ultrasound devices. Today, about 100,000 coronary bypass (CABG) procedures are performed in India annually, representing a market size of about half of the USA. The disproportionally low number of procedures compared to population size, as well as the growth in the general economy and health care investments, are expected to drive higher growth in CABG procedures in this market compared to the developed, western world. Hence, India is an important market for Medistim's long term strategy and growth.

As the cost of a CABG procedure in India is significantly lower than in many other markets, Medistim has a 2-tier product strategy in this market, offering both a lower-priced entry-level flowmeter, as well as a high-end portfolio with high frequency ultrasound imaging (HFUS) as an additional option.

As of January 1st, 2021, LivaNova will represent Medistim in India, through its Cardiovascular business unit. LivaNova is a

www.medistim.com

globally operating medical device manufacturer with a strong foothold in cardiac surgery. They are a market leader within heart-lung machines, hence targeting the same target customers as Medistim's intraoperative ultrasound devices. LivaNova has already proven to be a strong partner for Medistim in Australia.

Medistim has decided to go to market with special configuration of MiraQ for an entry-level alternative for price sensitive markets. The SonoQ products will be faced out. The decision is made due to the ever-increasing regulatory burden and cost of keeping two product families in parallel. With this change, Medistim will be able to continue to pursue their strategy and serve customers in India together with their new distributor, LivaNova, as planned, but at a lower total cost for Medistim.

Rest of the World

Sales in 'Rest of the World' decreased from MNOK 3.0 to MNOK 2.5 for the quarter and for 2020 sales declined from 21.9 MNOK to 16.7 MNOK. In total, these are small markets with wide variations from quarter to quarter.

PROSPECTS AND TRENDS

Goals and vision

The company aims to develop products to meet surgeons' growing need for quality control of heart bypass surgery, peripheral vascular surgery and transplant surgery. Our vision is that Medistim's solutions shall represent the "standard of care" for clinical practice and that blood flow measurements and intraoperative ultrasound imaging are performed on all patients.

Strategy

Medistim's focus is to strengthen the company's ability to effectively commercialize its product portfolio on a global basis. One of the key tasks to achieve this is closer contact with customers through a strengthened sales and marketing organization. Another important task is to produce enhanced clinical documentation and focus on putting blood flow measurements, ultrasound imaging, surgical guidance and quality assurance on the agenda of medical associations and in other relevant forums and channels.

Continuous technology and product development will secure Medistim's products and leading position within cardiac surgery in the future. The company also has ambitions to build and develop a similar position within vascular and transplant surgery.

Market size and trends

On a global basis, more than 700,000 heart bypass surgeries are performed each year. The U.S. represents the largest market for Medistim's products, with 1/3 of the world market. The global number of procedures has kept stable over the

past several years. The decrease in the number of procedures performed in the Western countries has been compensated by an increase in the BRICS countries (Brazil, Russia, India, China and South Africa). A stable to growing trend is therefore expected in the years to come.

Adding intraoperative ultrasound imaging to flow measurements more than doubles Medistim's market potential thanks to new applications and relevance and higher pricing compared to traditional flow measurement technology. Total market size within cardiac surgery is estimated to be NOK 2 billion annually. The imaging functionality makes MiraQ™ relevant in other cardiac surgeries and not just bypass surgery. Medistim estimates this potential to be NOK 1 billion.

In addition, the company has a significant potential within the global vascular market, which is estimated to be about 600,000 vascular procedures annually. Total market size within vascular surgery is estimated to be over NOK 1 billion.

The trend in surgery is moving towards minimally invasive and keyhole procedures, which gives the surgeon less workspace and ability to verify in a traditional way. There is therefore an increased need to verify the desired result in the future.

Global demographic trends are an important driving force for the many cost-efficiency measures around the world. Focus on quality is growing, driven by the need to reduce costs, particularly related to correction of errors, the need for repeated treatments and repeated hospital admissions. Medistim therefore has a good opportunity to position its products as an important contributor to achieving these goals.

Position and Competition

Medistim's flow meters have been in use in more than two million patients worldwide since entering the market, and the company is the clear leader in its niche. In total, Medistim has installed 3,000 systems in more than 60 countries. The equipment is used today in about 33% of the total number of bypass surgeries performed worldwide. Medistim's penetration and market share are expected to grow gradually as quality assurance in surgery is getting increasing attention and acceptance.

There are competitors that use the transit time measurement principle. Equipment from competitors is estimated to be in use in about 7% of the procedures performed. This means that in about 60% of the cases where bypass surgery is performed there is no equipment in use to verify blood flow. This market represents Medistim's largest opportunity. With Medistim's ultrasound imaging technology and MiraQ™ platform, the company has acquired a new edge compared to its competitors, with unique and differentiated products that are currently alone in their segment.

Exposure towards currency

The company is exposed to EUR and USD. Exposure can vary depending on the share of its revenues and costs in USD and EUR relative to its total income and expenses. For 2020, a 10% change in the exchange rate against USD and EUR would result in an 8.1% change in sales and a 13.7% change in operating result. The company partly secures its positions with hedging contracts.

The COVID-19 pandemic

The fourth quarter results continue to show a negative effect of the COVID-19 pandemic, as the total currency neutral sales revenues was down by 7.2%. Although the pandemic affects the US quite hard in the 4th quarter with a 27.8% decline in USD compared to same quarter in 2019, the negative impact on the global business is less than in the second and third quarter.

Due to lower operating costs from no travelling, conferences, and general cost containment, Medistim reports an EBIT result that is better both for the fourth quarter and for 2020 compared to last year. Cash flow from operation was a solid MNOK 74.3 and the cash position was MNOK 71.9 after a dividend of MNOK 50.1 was paid in the fourth quarter.

While Medistim has been affected by the COVID 19 situation, the company have been able to deliver solid profit and cash flow. The need for Medistim's products has not changed, hence the expectation is that it is only a matter of time before cardiac bypass surgeries are back to normal.

The situation is being continuously monitored, contingency plans are in place and the level of measures are being adjusted as appropriate.

SHAREHOLDER INFORMATION

The company had 136,500 Medistim shares by the end of December 2020. The shares were purchased at a price per share of NOK 14.70. The share price was NOK 250.00 per share at the end of the quarter. For comparison, entering 2020 the share price was NOK 192.00 per share.


The number of shares sold in the fourth quarter of 2020 totaled 1,682,473. The five largest shareholders were Intertrade Shipping AS with 2,000,000 shares, Salvesen & Thams Invest AS with 1,862,500 shares, Odin Fondene with 1,800,000 shares, State Street Bank with 1,171,599 shares and SEB Europafond with 1,040,407 shares.

Due to the COVID 19 situation, The Board of Directors received an authorization on the Annual General Meeting to resolve a dividend based on the financial statements for the financial year 2019. Payment of dividend was revaluated at the October 21st board meeting. Based upon the development and a positive future outlook for Medistim, the


Board of Directors decided to pay out the previously proposed dividend in full, NOK 2.75 per share. The shares were traded ex dividend the 22nd of October 2020. The dividend was paid out on the 4th of November 2020.

The Board will suggest to the General meeting a dividend of NOK 3.00 per share based upon the 2020 results.

Sales per quarter in TNOK




Operating profit per quarter in TNOK



Dividend per share in NOK

***2021 is the Boards suggested dividend**



Oslo, February 26th, 2021,
Board of Directors and CEO of Medistim ASA

Øyvinn A. Brøymer
Chairman
Sign.

Tove Raanes
Board member
Sign.

Bjørn M. Wiggen
Deputy Chairman
Sign.

Siri Fürst
Board member
Sign.

Lars Rønn
Board member
Sign.

Kari Eian Krogstad
CEO
Sign.

Profit & loss	4. quarter 20	4. quarter 19	2020	2019
All numbers in NOK 1000				
Sales	94 184	95 672	363 133	363 723
Cost of goods sold	22 232	19 836	76 577	80 138
Salary and sosial expenses	32 177	35 184	119 066	122 016
Other operating expenses	11 348	16 103	48 865	53 790
Total operating expenses	65 756	71 123	244 508	255 944
Opr. res.before. depr. and write offs	28 429	24 549	118 626	107 778
<i>Opr. res before depr and write off %</i>	<i>30,18 %</i>	<i>25,66 %</i>	<i>32,67 %</i>	<i>29,63 %</i>
Depreciation	6 293	4 796	23 141	18 010
Operating result	22 136	19 753	95 484	89 768
EBIT %	23,50 %	20,65 %	26,29 %	24,68 %
Financial income	1 433	7 888	14 137	6 649
Financial expenses	3 648	7 492	18 015	5 373
Net finance	(2 216)	397	(3 878)	1 276
Pre tax profit	19 920	20 150	91 606	91 044
Tax	6 352	4 662	22 219	20 738
Result	13 568	15 488	69 387	70 306
Dividend	50 052	-	50 052	40 925
Comprehensive income				
Result after tax	13 568	15 488	69 387	70 306
Exchange differences arising on translation of foreign operations	(6 490)	(2 626)	(965)	(87)
Total comprehensive income	7 078	12 862	68 422	70 219
Key figures				
	4. quarter 20	4. quarter 19	2020	2019
Equity share	74,27 %	70,47 %	74,27 %	70,47 %
Earnings per share	0,75	0,85	3,81	3,87
Earnings per share diluted	0,74	0,85	3,80	3,86
Average shares outstanding in 1000	18 200	18 188	18 200	18 188
Average shares outstanding in 1000 diluted	18 237	18 222	18 237	18 222

Split of operating				
result per segment	4. quarter 20	4. quarter 19	2020	2019
All numbers in NOK 1000				
Res from Medistim products	18 410	17 111	86 334	79 883
Margin Medistim products	25,24 %	21,46 %	29,21 %	27,02 %
Res from 3. party products	3 726	2 642	9 150	9 885
Margin 3. party products	17,54 %	16,60 %	13,55 %	14,52 %
Totalt result	22 136	19 753	95 484	89 768
Margin	23,50 %	20,65 %	26,29 %	24,68 %

Balance sheet	31.12.2020	31.12.2019
All numbers in NOK 1000		
Assets		
Intangible assets	33 463	40 773
Fixed assets	66 570	66 835
Total tangible and fixed assets	100 033	107 608
Inventory	112 667	90 070
Customers receivables	57 485	62 188
Other receivables	3 744	9 497
Cash	71 891	66 745
Total current assets	245 787	228 501
Total assets	345 820	336 109
Equity and liability		
Share capital	4 585	4 585
Share premium reserve	44 172	44 172
Other equity	208 089	188 104
Total equity	256 846	236 861
Long term debt		
Lease obligations	21 652	22 683
Deferred income	265	618
Other long term debt	7 580	4 500
Total long term debt	29 497	27 801
Total short term debt	59 477	71 447
Total equity and liability	345 820	336 109
Net interest bearing debt	(19 450)	(15 528)

Change in equity	31.12.2020	31.12.2019
All numbers in NOK 1000		
Equity start of period	236 861	206 712
Result for the period	69 387	70 306
Dividend	(50 052)	(40 925)
Medistim shares	1 615	854
Changes in exchangerates	(965)	(87)
Equity end of period	256 846	236 861

Cash flow analysis	31.12.2020	31.12.2019
All numbers in NOK 1000		
Result for the period	69 387	70 306
Other cash flow from operation	4 946	10 075
Cash flow from operation	74 333	80 380
Investments	(10 639)	(13 682)
Cash flow from financing	(58 549)	(47 444)
Change in cash for the period	5 145	19 254
Cash at start of period	66 745	47 491
Cash by the end of period	71 891	66 745

Geographic split of sales	4. quarter 20	4. quarter 19	2020	2019
All numbers in NOK 1000				
USA	26 974	35 135	126 408	136 094
Asia	8 844	10 743	46 811	41 790
Europe	55 841	46 790	173 263	163 863
Rest of the world	2 525	3 004	16 651	21 975
Total sales	94 184	95 672	363 133	363 723

Geographic split of sales in number of units	4. quarter 20	4. quarter 19	2020	2019
USA				
Procedures flow measurement only	11 964	12 834	47 256	52 206
Procedures imaging	1 935	2 818	8 803	10 233
Capital sales MiraQ flowmeasurement instrument	2	1	14	14
Capital sales MiraQ imaging and flowmeasurement instrument	1	7	12	19
Lease flow instrument	3	3	10	6
Lease imaging and flow instrument	3	5	3	13
Asia				
MiraQ and VeriQ flowmeasurement instrument	9	18	63	40
MiraQ and VeriQC imaging and flowmeasurement instrument	3	1	19	25
Imaging probes	1	3	26	28
Flowmeasurement probes	463	655	1 693	1 909
Europe				
MiraQ flowmeasurement instrument	22	21	52	54
MiraQ imaging and flowmeasurement instrument	9	6	19	20
Imaging probes	16	10	36	25
Flowmeasurement probes	1 167	1 093	3 943	4 269
Rest of the world				
MiraQ flowmeasurement instrument	(1)	-	9	8
MiraQ imaging and flowmeasurement instrument	1	2	9	15
Imaging probes	5	4	13	25
Flowmeasurement probes	138	150	582	1 012
Total sales outside the US in units				
Number of MiraQ and VeriQ flow instruments outside USA	30	39	124	102
MiraQ and VeriQC imaging and flow instruments	13	9	47	60
Total number of imaging probes	22	17	75	78
Total number of flowmeasurement probes outside USA	1 768	1 898	6 218	7 190

Split of sales per segment	4. quarter 20	4. quarter 19	2020	2019
All numbers in NOK 1000				
USA				
Procedural revenue flow	17 870	21 836	75 484	83 185
Procedural revenue Imaging and flow	5 489	6 414	23 892	23 540
Capital sales MiraQ flowmeasurement instruments	2 796	57	12 022	9 852
Capital sales MiraQ imaging and flowmeasurement instrument	819	6 828	15 011	19 517
Outside USA				
MiraQ and VeriQ flowmeasurement instrument	10 683	8 481	35 225	23 047
MiraQ and VeriQC imaging and flowmeasurement instrument	9 149	4 897	29 179	29 725
Imaging probes	1 291	1 052	5 219	5 000
Flowmeasurement probes	22 831	26 601	92 626	94 985
Other	2 016	3 588	6 927	6 809
Total sale of Medistim prod.	72 944	79 754	295 585	295 660
Sale of 3. party products	21 240	15 919	67 549	68 063
Total sales	94 184	95 673	363 134	363 723

Split of sales between coronary and vascular surgery and 3 party products	4. quarter 20	4. quarter 19	2020	2019
All numbers in NOK 1000				
Sales within coronary surgery	61 703	64 636	250 482	252 371
Sales within vascular surgery	11 241	15 118	45 102	43 289
Sales of 3. party products	21 240	15 919	67 549	68 063
Total sales	94 184	95 673	363 133	363 723